Opportunity Information: Apply for RFA OD 20 023
Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds) is a National Institutes of Health (NIH) funding opportunity (RFA-OD-20-023) designed to rapidly support research that improves how clinicians detect, classify, and anticipate COVID-19 related inflammatory illness in children. The core goal is to push beyond traditional testing and develop novel or non-traditional diagnostic and prognostic approaches, such as biomarkers and multi-marker biosignatures, that can better capture the full spectrum of SARS-CoV-2 associated pediatric disease. A major emphasis is on multisystem inflammatory syndrome in children (MIS-C), a serious condition linked to SARS-CoV-2 that can appear after infection and involve multiple organs, with severity varying widely across patients.
A central feature of the opportunity is the expectation that funded projects will not only identify and characterize indicators of disease, but also translate those indicators into a prognostic algorithm capable of predicting a child s longitudinal risk of developing severe outcomes after exposure to, and possible infection with, SARS-CoV-2. In practical terms, this means developing laboratory diagnostics paired with artificial intelligence or other advanced analytic methods to estimate risk over time, rather than offering a single snapshot. The intended payoff is clinically actionable risk stratification that helps tailor management decisions to the individual child, supporting earlier intervention for those likely to worsen and avoiding unnecessary escalation for those likely to recover without severe complications.
The mechanism is an NIH R61/R33 phased innovation award, with clinical trials listed as optional. That structure is typically used to support projects that need an early, milestone-driven development phase followed by a second phase focused on expansion, validation, or more advanced testing once feasibility is demonstrated. While the announcement is positioned as an emergency award under the RADx-rad effort, the scientific focus is squarely on pediatric inflammatory disease severity prediction using laboratory diagnostics and AI-enabled decision tools.
In terms of eligibility, the FOA is broad and includes many organizational types that could contribute to pediatric clinical research, diagnostics development, data science, and community-based enrollment or implementation. Eligible applicants include state, county, city or township, and special district governments; independent school districts; public housing authorities; public and private institutions of higher education; nonprofits with or without 501(c)(3) status; for-profit organizations (including those other than small businesses); and small businesses, as well as federally recognized tribal governments and other tribal organizations. The announcement also explicitly highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, regional organizations, eligible federal agencies, U.S. territories or possessions, and even non-U.S. (foreign) organizations. This wide eligibility aligns with the urgent, multidisciplinary nature of the problem and the need to reach diverse pediatric populations.
Administratively, this is a discretionary grant opportunity under NIH, categorized within the broader public purposes of education, health, and social services, and linked to multiple CFDA numbers (93.233, 93.279, 93.307, 93.310, 93.837, 93.838, 93.839, 93.840, 93.846, 93.855, 93.865, 93.989). The original closing date was September 30, 2020, and the award ceiling listed is $500,000. Overall, the opportunity is aimed at accelerating practical tools that combine next-generation lab measurements with AI-driven analytics to help clinicians predict which children are most at risk for severe SARS-CoV-2 associated inflammatory disease and to improve outcomes through better-timed, better-targeted care.Apply for RFA OD 20 023
- The National Institutes of Health in the education, health, income security and social services sector is offering a public funding opportunity titled "Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds) (R61/R33 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.233, 93.279, 93.307, 93.310, 93.837, 93.838, 93.839, 93.840, 93.846, 93.855, 93.865, 93.989.
- This funding opportunity was created on 2020-08-06.
- Applicants must submit their applications by 2020-09-30. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the name of this funding opportunity?
The opportunity is titled "Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds)."
Which agency is offering this grant?
This is a National Institutes of Health (NIH) funding opportunity.
What is the FOA number for this opportunity?
The FOA number is RFA-OD-20-023.
What is the main purpose of the PreVAIL kIds program?
The purpose is to rapidly support research that improves how clinicians detect, classify, and anticipate COVID-19 related inflammatory illness in children, especially by developing laboratory diagnostics and AI-enabled analytic approaches that predict disease severity over time.
What pediatric condition is a major emphasis of this FOA?
A major emphasis is multisystem inflammatory syndrome in children (MIS-C), a serious SARS-CoV-2-associated condition that can occur after infection and may involve multiple organs with widely varying severity.
What kinds of approaches does the FOA encourage beyond traditional testing?
The FOA encourages novel or non-traditional diagnostic and prognostic approaches, including biomarkers and multi-marker biosignatures, intended to better capture the full spectrum of SARS-CoV-2-associated pediatric disease.
What is expected beyond identifying biomarkers or indicators of disease?
Funded projects are expected not only to identify and characterize indicators of disease, but also to translate those indicators into a prognostic algorithm that predicts a child's longitudinal risk of severe outcomes after exposure to, and possible infection with, SARS-CoV-2.
What does "longitudinal risk" mean in the context of this announcement?
It refers to estimating risk over time rather than providing a single point-in-time result, with the goal of predicting whether a child is likely to worsen or recover without severe complications.
How does artificial intelligence fit into the goals of this FOA?
AI (or other advanced analytic methods) is expected to be paired with laboratory diagnostics to support risk estimation and decision tools that enable clinically actionable risk stratification.
What is the intended clinical payoff of the work funded under this program?
The intended payoff is clinically actionable risk stratification to support individualized management decisions, enabling earlier intervention for children likely to deteriorate and helping avoid unnecessary escalation for children likely to recover without severe complications.
What funding mechanism is used for this opportunity?
The mechanism is an NIH R61/R33 phased innovation award.
What does an R61/R33 phased innovation award generally imply for project structure?
It typically supports an early, milestone-driven development phase followed by a second phase focused on expansion, validation, or more advanced testing after feasibility is demonstrated.
Are clinical trials required under this FOA?
Clinical trials are listed as optional.
Is this opportunity part of a broader NIH initiative?
Yes. The announcement is positioned as an emergency award under the RADx-rad effort.
What is the scientific focus of the FOA?
The scientific focus is pediatric inflammatory disease severity prediction using laboratory diagnostics and AI-enabled decision tools in the context of SARS-CoV-2-associated illness.
Who is eligible to apply?
Eligibility is broad and includes many organizational types, such as state, county, city or township, and special district governments; independent school districts; public housing authorities; public and private institutions of higher education; nonprofits with or without 501(c)(3) status; for-profit organizations (including those other than small businesses); and small businesses; as well as federally recognized tribal governments and other tribal organizations.
Are U.S. territories or possessions eligible to apply?
Yes. U.S. territories or possessions are explicitly listed among eligible applicants.
Are non-U.S. (foreign) organizations eligible to apply?
Yes. The announcement explicitly includes non-U.S. (foreign) organizations as eligible applicants.
Does the FOA mention specific categories of institutions and organizations as eligible applicants?
Yes. It explicitly highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, regional organizations, eligible federal agencies, and others listed in the announcement.
What types of organizations does this broad eligibility aim to support?
Based on the description, the broad eligibility is intended to align with the urgent, multidisciplinary nature of pediatric disease severity prediction and the need to reach diverse pediatric populations through clinical research, diagnostics development, data science, enrollment, and implementation capabilities.
Is this a discretionary grant opportunity?
Yes. It is described as a discretionary grant opportunity under NIH.
How is this opportunity categorized in terms of public purpose?
It is categorized within the broader public purposes of education, health, and social services.
Which CFDA numbers are associated with this opportunity?
The opportunity is linked to multiple CFDA numbers: 93.233, 93.279, 93.307, 93.310, 93.837, 93.838, 93.839, 93.840, 93.846, 93.855, 93.865, and 93.989.
What was the original closing date for this opportunity?
The original closing date was September 30, 2020.
What is the award ceiling listed for this FOA?
The listed award ceiling is $500,000.
What is the overall goal of the opportunity in practical terms?
Overall, it aims to accelerate practical tools that combine next-generation laboratory measurements with AI-driven analytics to help clinicians predict which children are most at risk for severe SARS-CoV-2-associated inflammatory disease and improve outcomes through better-timed, better-targeted care.
Browse more opportunities from the same category: Education, Health, Income Security and Social Services
Next opportunity: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)
Previous opportunity: Collaborative Centers in Children's Environmental Health Research and Translation Centers (P2C Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA OD 20 023
Applicants also applied for:
Applicants who have applied for this opportunity (RFA OD 20 023) also looked into and applied for these:
| Funding Opportunity |
|---|
| Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (Fast-Track STTR Clinical Trial Not Allowed) Apply for RFA OD 20 021 Funding Number: RFA OD 20 021 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Pilot resources for brain cell type-specific access and manipulation across vertebrate species (U01 Clinical Trial Not Allowed) Apply for RFA MH 20 556 Funding Number: RFA MH 20 556 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative Fellows: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32) Apply for RFA MH 20 620 Funding Number: RFA MH 20 620 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative Cell Census Network (BICCN) Scalable Technologies and Tools for Brain Cell Census (R01 Clinical Trial Not Allowed) Apply for RFA MH 21 140 Funding Number: RFA MH 21 140 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed) Apply for RFA EY 21 001 Funding Number: RFA EY 21 001 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required) Apply for PAR 21 144 Funding Number: PAR 21 144 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed) Apply for PAR 21 145 Funding Number: PAR 21 145 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Firearm Injury and Mortality Prevention Research (R01Clinical Trial Optional) Apply for PAR 21 192 Funding Number: PAR 21 192 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Firearm Injury and Mortality Prevention Research (R21/R33 Clinical Trial Optional) Apply for PAR 21 191 Funding Number: PAR 21 191 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed) Apply for RFA MH 21 135 Funding Number: RFA MH 21 135 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) Apply for PAR 21 163 Funding Number: PAR 21 163 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Secondary Analysis and Archiving of BRAIN Initiative Data (R01 Clinical Trial Not Allowed) Apply for RFA MH 21 130 Funding Number: RFA MH 21 130 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $300,000 |
| Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) Apply for PAR 21 162 Funding Number: PAR 21 162 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Limited Interaction Targeted Epidemiology (LITE-2): To Advance HIV Prevention (UG3/UH3 Clinical Trial Optional) Apply for RFA AI 21 018 Funding Number: RFA AI 21 018 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access and Manipulation to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed) Apply for RFA MH 21 180 Funding Number: RFA MH 21 180 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) Apply for PAR 21 233 Funding Number: PAR 21 233 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed) Apply for RFA MH 21 175 Funding Number: RFA MH 21 175 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional) Apply for RFA NS 21 023 Funding Number: RFA NS 21 023 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $1,000,000 |
| BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional) Apply for RFA NS 21 024 Funding Number: RFA NS 21 024 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $1,500,000 |
| Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Required) Apply for PAR 21 154 Funding Number: PAR 21 154 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $300,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA OD 20 023", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.